These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 25870132)

  • 1. Discovery and hit-to-lead optimization of 2,6-diaminopyrimidine inhibitors of interleukin-1 receptor-associated kinase 4.
    McElroy WT; Michael Seganish W; Jason Herr R; Harding J; Yang J; Yet L; Komanduri V; Prakash KC; Lavey B; Tulshian D; Greenlee WJ; Sondey C; Fischmann TO; Niu X
    Bioorg Med Chem Lett; 2015 May; 25(9):1836-41. PubMed ID: 25870132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.
    Seganish WM; McElroy WT; Herr RJ; Brumfield S; Greenlee WJ; Harding J; Komanduri V; Matasi J; Prakash KC; Tulshian D; Yang J; Yet L; Devito K; Fossetta J; Garlisi CG; Lundell D; Niu X; Sondey C
    Bioorg Med Chem Lett; 2015 Aug; 25(16):3203-7. PubMed ID: 26115573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A hit to lead discovery of novel N-methylated imidazolo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors.
    Lee W; Ortwine DF; Bergeron P; Lau K; Lin L; Malek S; Nonomiya J; Pei Z; Robarge KD; Schmidt S; Sideris S; Lyssikatos JP
    Bioorg Med Chem Lett; 2013 Sep; 23(18):5097-104. PubMed ID: 23932790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of N6-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine derivatives as novel CK1 inhibitors using common-feature pharmacophore model based virtual screening and hit-to-lead optimization.
    Yang LL; Li GB; Yan HX; Sun QZ; Ma S; Ji P; Wang ZR; Feng S; Zou J; Yang SY
    Eur J Med Chem; 2012 Oct; 56():30-8. PubMed ID: 22944772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design.
    Lee KL; Ambler CM; Anderson DR; Boscoe BP; Bree AG; Brodfuehrer JI; Chang JS; Choi C; Chung S; Curran KJ; Day JE; Dehnhardt CM; Dower K; Drozda SE; Frisbie RK; Gavrin LK; Goldberg JA; Han S; Hegen M; Hepworth D; Hope HR; Kamtekar S; Kilty IC; Lee A; Lin LL; Lovering FE; Lowe MD; Mathias JP; Morgan HM; Murphy EA; Papaioannou N; Patny A; Pierce BS; Rao VR; Saiah E; Samardjiev IJ; Samas BM; Shen MWH; Shin JH; Soutter HH; Strohbach JW; Symanowicz PT; Thomason JR; Trzupek JD; Vargas R; Vincent F; Yan J; Zapf CW; Wright SW
    J Med Chem; 2017 Jul; 60(13):5521-5542. PubMed ID: 28498658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of potent, selective, and orally bioavailable inhibitors of interleukin-1 receptor-associate kinase-4.
    Wang Z; Sun D; Johnstone S; Cao Z; Gao X; Jaen JC; Liu J; Lively S; Miao S; Sudom A; Tomooka C; Walker NP; Wright M; Yan X; Ye Q; Powers JP
    Bioorg Med Chem Lett; 2015 Dec; 25(23):5546-50. PubMed ID: 26526214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation.
    Smith GF; Altman MD; Andresen B; Baker J; Brubaker JD; Chen H; Chen Y; Childers M; Donofrio A; Ferguson H; Fischer C; Fischmann TO; Gibeau C; Hicks A; Jin S; Kattar S; Kleinschek MA; Leccese E; Lesburg C; Li C; Lim J; Liu D; Maclean JKF; Mansoor F; Moy LY; Mulrooney EF; Necheva AS; Presland J; Rakhilina L; Yang R; Torres L; Zhang-Hoover J; Northrup A
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2721-2726. PubMed ID: 28501511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders.
    Chaudhary D; Robinson S; Romero DL
    J Med Chem; 2015 Jan; 58(1):96-110. PubMed ID: 25479567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases.
    McClellan WJ; Dai Y; Abad-Zapatero C; Albert DH; Bouska JJ; Glaser KB; Magoc TJ; Marcotte PA; Osterling DJ; Stewart KD; Davidsen SK; Michaelides MR
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5620-4. PubMed ID: 21778056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors.
    Bryan MC; Drobnick J; Gobbi A; Kolesnikov A; Chen Y; Rajapaksa N; Ndubaku C; Feng J; Chang W; Francis R; Yu C; Choo EF; DeMent K; Ran Y; An L; Emson C; Huang Z; Sujatha-Bhaskar S; Brightbill H; DiPasquale A; Maher J; Wai J; McKenzie BS; Lupardus PJ; Zarrin AA; Kiefer JR
    J Med Chem; 2019 Jul; 62(13):6223-6240. PubMed ID: 31082230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and SAR of 2-phenoxypyridines as novel c-Jun N-terminal kinase inhibitors.
    Song X; Chen W; Lin L; Ruiz CH; Cameron MD; Duckett DR; Kamenecka TM
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7072-5. PubMed ID: 22004719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of pyrazolo[1,5-a]pyrimidine-based Pim inhibitors: a template-based approach.
    Dwyer MP; Keertikar K; Paruch K; Alvarez C; Labroli M; Poker C; Fischmann TO; Mayer-Ezell R; Bond R; Wang Y; Azevedo R; Guzi TJ
    Bioorg Med Chem Lett; 2013 Nov; 23(22):6178-82. PubMed ID: 24091081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and optimization of a potent and selective indazolamine series of IRAK4 inhibitors.
    Zhai W; Lu Y; Zhu Y; Zhou M; Ye C; Shi ZZ; Qian W; Hu T; Chen L
    Bioorg Med Chem Lett; 2021 Jan; 31():127686. PubMed ID: 33242574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of BIO-8169─A Highly Potent, Selective, and Brain-Penetrant IRAK4 Inhibitor for the Treatment of Neuroinflammation.
    Pfaffenbach M; Bolduc PN; Xin Z; Gao F; Evans R; Fang T; Chodaparambil JV; Henry KL; Li P; Mathieu S; Metrick C; Vera Rebollar JA; Gu RF; Mccarl CA; Silbereis J; Peterson EA
    J Med Chem; 2024 May; 67(10):8383-8395. PubMed ID: 38695469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors.
    Bhide RS; Keon A; Weigelt C; Sack JS; Schmidt RJ; Lin S; Xiao HY; Spergel SH; Kempson J; Pitts WJ; Carman J; Poss MA
    Bioorg Med Chem Lett; 2017 Nov; 27(21):4908-4913. PubMed ID: 28947151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): kinase profiling guided optimization of a 1,2,3-benzotriazole lead.
    Palmer WS; Alam M; Arzeno HB; Chang KC; Dunn JP; Goldstein DM; Gong L; Goyal B; Hermann JC; Hogg JH; Hsieh G; Jahangir A; Janson C; Jin S; Ursula Kammlott R; Kuglstatter A; Lukacs C; Michoud C; Niu L; Reuter DC; Shao A; Silva T; Trejo-Martin TA; Stein K; Tan YC; Tivitmahaisoon P; Tran P; Wagner P; Weller P; Wu SY
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1486-92. PubMed ID: 23352510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of potent and selective PKC-theta inhibitors.
    Cywin CL; Dahmann G; Prokopowicz AS; Young ER; Magolda RL; Cardozo MG; Cogan DA; Disalvo D; Ginn JD; Kashem MA; Wolak JP; Homon CA; Farrell TM; Grbic H; Hu H; Kaplita PV; Liu LH; Spero DM; Jeanfavre DD; O'Shea KM; White DM; Woska JR; Brown ML
    Bioorg Med Chem Lett; 2007 Jan; 17(1):225-30. PubMed ID: 17055721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efforts towards the optimization of a bi-aryl class of potent IRAK4 inhibitors.
    Hanisak J; Seganish WM; McElroy WT; Tang H; Zhang R; Tsui HC; Fischmann T; Tulshian D; Tata J; Sondey C; Devito K; Fossetta J; Garlisi CG; Lundell D; Niu X
    Bioorg Med Chem Lett; 2016 Sep; 26(17):4250-5. PubMed ID: 27476420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potency switch between CHK1 and MK2: discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.
    Meng Z; Ciavarri JP; McRiner A; Zhao Y; Zhao L; Reddy PA; Zhang X; Fischmann TO; Whitehurst C; Arshad Siddiqui M
    Bioorg Med Chem Lett; 2013 May; 23(10):2863-7. PubMed ID: 23587425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of selective 4-Amino-pyridopyrimidine inhibitors of MAP4K4 using fragment-based lead identification and optimization.
    Crawford TD; Ndubaku CO; Chen H; Boggs JW; Bravo BJ; Delatorre K; Giannetti AM; Gould SE; Harris SF; Magnuson SR; McNamara E; Murray LJ; Nonomiya J; Sambrone A; Schmidt S; Smyczek T; Stanley M; Vitorino P; Wang L; West K; Wu P; Ye W
    J Med Chem; 2014 Apr; 57(8):3484-93. PubMed ID: 24673130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.